OTCMKTS:IGXT IntelGenx Technologies (IGXT) Stock Price, News & Analysis $0.17 0.00 (0.00%) As of 10/30/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartSEC Filings About IntelGenx Technologies Stock (OTCMKTS:IGXT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get IntelGenx Technologies alerts:Sign Up Key Stats Today's Range$0.17▼$0.1750-Day Range$0.17▼$0.1752-Week Range$0.09▼$0.22VolumeN/AAverage VolumeN/AMarket Capitalization$29.17 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview IntelGenx Technologies Corp. is a Canadian pharmaceutical company focused on developing and commercializing oral drug-delivery products. The company’s proprietary VersaFilm technology is designed to deliver active pharmaceutical ingredients through thin, rapidly dissolving films placed in the mouth, offering an alternative to conventional tablets and capsules. IntelGenx has developed film-based products for a range of therapeutic applications, including migraine treatment and other prescription and over-the-counter medicines. Its development activities have included products based on zolmitriptan, the active ingredient in migraine medication, as well as oral films incorporating other pharmaceutical compounds. The company also evaluates licensing, partnering, and contract-development opportunities involving its delivery platform. IntelGenx is headquartered in Montreal, Quebec, and has pursued commercialization opportunities in North America and international markets through regulatory filings and strategic partnerships. The company has historically been led by Dr. Horst G. Zerbe, a co-founder and longtime executive associated with its pharmaceutical-film development programs.AI Generated. May Contain Errors. Read More Receive IGXT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IntelGenx Technologies and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IGXT Stock News HeadlinesIntelgenx Technologies (OTC:IGXT) Stock Quotes, Forecast and News SummaryAugust 18, 2024 | benzinga.comIntelGenx Technologies Corp.: IntelGenx Provides Update on Previously Announced Sale and Investment Solicitation ProcessJuly 20, 2024 | finanznachrichten.deSomething I owe you todayThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now he's filed to launch 1,000,000 AI satellites, a move Dylan believes could mean a 100X bigger royalty bill starting December 8th. This free pick names the public company collecting on every unit.November 4 at 1:00 AM | Behind the Markets (Ad)IntelGenx Provides Update on Previously Announced Sale and Investment Solicitation ProcessJuly 19, 2024 | globenewswire.comIntelGenx Obtains Preliminary Efficacy Results for the ‘BUENA' Montelukast VersaFilm® Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer's DiseaseJuly 3, 2024 | globenewswire.comIntelGenx Announces Initiation of the Sale and Investment Solicitation ProcessJune 11, 2024 | globenewswire.comIntelGenx Obtains Court-Approval of a Sale and Investment Solicitation ProcessMay 28, 2024 | globenewswire.comIntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic AlternativesMay 17, 2024 | globenewswire.comSee More Headlines IGXT Stock Analysis - Frequently Asked Questions How have IGXT shares performed this year? IntelGenx Technologies' stock was trading at $0.1670 at the beginning of the year. Since then, IGXT stock has increased by 0.0% and is now trading at $0.1670. How were IntelGenx Technologies' earnings last quarter? IntelGenx Technologies Corp. (OTCMKTS:IGXT) posted its quarterly earnings results on Thursday, November, 12th. The company reported ($0.01) earnings per share for the quarter, beating analysts' consensus estimates of ($0.02) by $0.01. The business earned $510 thousand during the quarter. How do I buy shares of IntelGenx Technologies? Shares of IGXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of IntelGenx Technologies own? Based on aggregate information from My MarketBeat watchlists, some other companies that IntelGenx Technologies investors own include Advanced Micro Devices (AMD), NIO (NIO), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK) and Pfizer (PFE). Company Calendar Last Earnings11/12/2020Today11/04/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:IGXT CIK1098880 Webwww.intelgenx.com Phone(514) 331-7440Fax514-331-0436Employees38Year Founded2003Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$1.04 million Price / Sales28.05 Cash FlowN/A Price / Cash FlowN/A Book Value($0.07) per share Price / Book-2.39Miscellaneous Outstanding Shares174,658,000Free Float101,214,000Market Cap$29.17 million OptionableNot Optionable Beta2.47 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (OTCMKTS:IGXT) was last updated on 10/30/2026 by MarketBeat.com Staff. From Our PartnersSomething I owe you todayThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredMany investors are about to lose everythingTwenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a househ...Porter & Company | SponsoredU.S. Army Advances 75-Year Rare Earth Deal With Nasdaq FirmThe Pentagon is moving to cut US dependence on Chinese rare earth metals, and a Nasdaq-listed company just sig...The Tomorrow Investor | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredElon Musk about to bankrupt Amazon, Microsoft & Google?Jeff Brown, the former tech executive who called the rise of Bitcoin, Tesla, and Nvidia years early, is tracki...Brownstone Research | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredDoes your nest egg have an expiration date?A $250,000 nest egg growing at 5% a year and paying out $2,500 a month runs dry in just over a decade. Start w...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IntelGenx Technologies Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share IntelGenx Technologies With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
